cancers / breast cancers / cancer / disease / Urinary Tract Infection / hyperglycemia / Genital Infections / stroke / Genital Infection / Bladder Cancer / diabetes / unstable angina / Diabetes Mellitus / myocardial infarctions / moderately severe dapagliflozin-induced liver injury / bladder cancers / hypoglycemia / breast and bladder cancer / Breast Cancer / genitalurinary infections / /
OperatingSystem
OSE / /
Organization
Endocrinology Products Advisory Committee / Division of Metabolism and Endocrinology Products Through / M.P.H. Director office of Drug Evaluation / Food and Drug Administration / Endocrinology Products Office / Review Division / FDA / New Drugs Center for Drug Evaluation / Division of Metabolism / DEPARTMENT OF HEALTH / ADVISORY COMMITTEE / Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation / /
Person
Mary H. Parks / Ilan Irony / Somya V. Dunn / Silver Spring / Curtis J. Rosebraugh / Somya Dunn / D. Mary H. Parks / Jonathan Norton / Anita Abraham / /
FDA BRIEFING DOCUMENT NDA[removed]DAPAGLIFLOZIN TABLETS, 5 AND 10 MG